|Bid||36.50 x 2900|
|Ask||40.76 x 1200|
|Day's Range||38.56 - 39.15|
|52 Week Range||35.10 - 46.80|
|PE Ratio (TTM)||10.30|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Index (PMI) data, output in the Healthcare sector is rising.
Stocks that moved substantially or traded heavily Thursday: Tesla Inc., down $16.70 to $284.45 The electric car maker took another big quarterly loss as it struggled to ramp up production of its Model ...
Wayfair Inc (NYSE: W ) - Bank of America on Wednesday upgraded from Neutral To Buy and lifted price target from $90 to $95; Says the company has built "solid scale" in the home goods category. ...
Hologic did report a sales beat in it Q2, but it was driven mostly by breast health sales that benefited from distribution acquisitions, Newitter said in a Thursday note. Molecular diagnostics excluding blood screening fell short of expectations due to poor weather trends, Newitter said. A better-than-expected contribution from blood screening yielded a "lower quality" revenue beat, he said.
Yesterday, after the market closed, Hologic (HOLX) released its 2Q18 earnings results for the quarter that ended on March 31. The company’s reported revenues exceeded analysts’ estimates, but the adjusted EPS (earnings per share) for the quarter barely met Wall Street estimates. For fiscal 2Q18, the company posted revenues of $789.3 million, representing YoY (year-over-year) revenue growth of ~10.3%.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...
MARLBOROUGH, Mass. (AP) _ Hologic Inc. (HOLX) on Wednesday reported a fiscal second-quarter loss of $681.4 million, after reporting a profit in the same period a year earlier. The results met Wall Street expectations. For the current quarter ending in July, Hologic expects its per-share earnings to range from 55 cents to 57 cents.
Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.
A strong Panther system and an increasing utilization of Aptima women's health assays add stimulus to Global growth within Hologic's (HOLX) molecular diagnostics.
athenahealth's (ATHN) strong product portfolio, network expansion strategies and unique business model are likely to drive Q1 earnings.
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
The hair and skin cosmetic procedure provider LightRx Face & Body announced a partnership Tuesday in which it will provide Hologic, Inc. (NASDAQ: HOLX )'s SculpSure non-invasive laser body contouring treatment ...
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 14. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $14.78 billion.
On February 22, 2018, Hologic (HOLX) announced that it has entered into an agreement with the University of Minnesota to be an exclusive provider of Dexalytics: Teams software in North America. The partnership is aimed at providing groundbreaking body composition analysis software to the sports science and human performance industry. The software harnesses the body composition data provided by the DXA (dual X-ray absorptiometry) scans and compares them with the predetermined standards specific to the sport and position.
Hologic’s (HOLX) Viera system is a one-of-a-kind wireless, handheld breast ultrasound system. On February 28, 2018, Hologic announced that it will present its Viera system at the annual ECR (European Congress of Radiology) in Vienna along with seven of its other market-leading breast and skeletal health innovations. The list includes the company’s fastest and highest resolution breast tomosynthesis system, the 3Dimensions Mammography System, which was launched in Europe in September 2017.
On March 2, 2018, Hologic (HOLX) announced a global partnership with Royal Philips (PHG) to provide an integrated health solution for women comprised of diagnostic imaging modalities and advanced informatics along with screening, diagnosis, and treatment services. According to the agreement, some of the selected products from Hologic’s breast health portfolio will be available for Royal Philips to offer as part of its multi-modality deals for healthcare providers, hospitals, and more. The selected products include Hologic’s breast screening technologies, interventional radiology technologies, and its 3Dimensions Mammography System, the fastest breast tomosynthesis system in the market.
On March 27, 2018, Hologic (HOLX) announced that its Clarity HD (high-definition) high-resolution 3D (three-dimensional) imaging and Intelligent 2D (two-dimensional) imaging technology has been approved by the FDA. The technologies are available for use on the company’s 3Dimensions Mammography System, the highest-resolution, fastest breast tomosynthesis system available in the market. Hologic’s 3Dimensions Mammography System was approved by the FDA in 2011.
Revenue, particularly in the Detection segment, continued to impress with very strong sales of the tomo (2D and 3D) products pushing total revenue up by 14% yoy. Detection product sales, up 100% yoy (pro-forma for ex-MRI), turned in the best quarter since Q3 2011 (when ICAD was still direct-selling MRI software) and crushed our number by 25%. While Q4 is typically ICAD’s strongest, the apparent accelerating adoption of the ‘legacy’ 2D and first-gen 3D tomo (GE-only) applications is obviously encouraging, particularly given the near-term launch of ICAD’s next-gen software.
When the market provides you with the opportunity to buy a strong business in a critical industry at a reasonable price, it's worth considering.
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss the latest market moves.